Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the
intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene …

OBJECTIVE—To examine the mechanisms of action, therapeutic potential, and challenges
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …

Background Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2
diabetes. We have investigated the long-term effects of continuous administration of this …

Palmitic acid hydroxystearic acids (PAHSAs) are endogenous lipids with anti-diabetic and
anti-inflammatory effects. PAHSA levels are reduced in serum and adipose tissue of insulin …

The glucagon-like peptides GLP-1 and GLP-2 are produced in enteroendocrine L cells of
the small and large intestine and secreted in a nutrient-dependent manner. GLP-1 regulates …

Peptide hormones exert unique actions via specific G protein–coupled receptors; however,
the therapeutic potential of regulatory peptides is frequently compromised by rapid …

Post‐translational proteolytic processing of the preproglucagon gene in the gut results in the
formation of glucagon‐like peptide 1 (GLP‐1). Owing to its glucose‐dependent …

Background Dahl salt-sensitive (Dahl S) rats exhibit many phenotypic traits associated with
salt-sensitive hypertension in man. Specifically, they are salt-sensitive, insulin-resistant and …

Glucagon-like peptide-1 (GLP-1) relaxes the stomach during fasting but decreases hunger
and food consumption and retards gastric emptying. The interrelationships between volume …

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that stimulates insulin secretion
and decreases glucagon release. It has been hypothesized that GLP-1 also reduces …